Adrenal Causes Together – International Collaboration for Endocrine Conditions
The CAH support group has been working with a group called ‘Adrenal Causes Together’ during the Covid-19 pandemic set-up by the Addison’s Disease Self-Help Group.
Patient support groups representing a range of different conditions from UK, Europe, Australia and the US together with Endocrine nurse specialists and Endocrinologists have been sharing information and meeting on-line to share information, explore new strategies and offer advice and support.
One of the actions from the group was to write an open letter to Endocrinologists and medical authorities in Brazil asking for specific support for those with adrenal insufficiency in Brazil at this difficult time and offer solidarity with those who are struggling to get the help and medical supplies they need. You can read the letter here.
We hope to continue contributing, supporting and learning with international groups in the future.
Recent Blog Posts
What you should know about COVID-19 – updated 10th August 2021
Guidance from other organizations is continually being issued and we'll do our best to link to them below - please keep checking back here for more updates. UPDATE 10th August 2021 Article: “ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises”...
New NICE Guidelines – identification and management of adrenal insufficiency
The publication of new NICE (National Institute for Health and Care Excellence) guidelines - "Adrenal insufficiency: identification and management" marks a significant advancement in the management and treatment of primary, secondary and tertiary adrenal...
Survey: Paediatric Adrenal Insufficiency Education
This project, led by Edge Hill University is working with NHS clinicians to develop national education standards and resources for sick day/emergency management of adrenal insufficiency in children and young people. The project would like to hear the views of parents...
Treatment Research Update – Crinetics Atumelnant (CRN04894)
Atumelnant (CRN04894) is in development by Crinetics for the treatment of congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. It is an oral, selective ACTH antagonist. Atumelnant is now in Phase 2 of development and you can read the latest...